CA
NZ
UK
AU
IND
US
Immuron (NASDAQ: IMRN) reported that unaudited global Travelan sales for fiscal year 2026 rose 6% to AUD$7.7 million, representing the fourth consecutive quarter of year-over-year growth for its flagship product — an important commercial milestone for a small-cap biotech company establishing consistent revenue growth …
Kairos Pharma (NASDAQ: KAPA) disclosed preliminary safety results from its Phase 1 clinical study evaluating ENV-105 in combination with osimertinib for patients with advanced EGFR-mutated non-small cell lung cancer, marking a key development for a program targeting one of oncology's most clinically pressing challenges: …
Lakewood-Amedex Biotherapeutics (OTC: LABT) reported encouraging preclinical safety results for its antimicrobial Nu-3 gel, establishing the foundational safety profile needed to advance into its anticipated Phase 2a clinical trial in patients with infected diabetic foot ulcers — a significant and growing area of unmet …
Galmed Pharmaceuticals (NASDAQ: GLMD) established a strategic partnership with Barcode Nanotech to engineer a novel lipid nanoparticle delivery system for Aramchol, the company's proprietary stearoyl-CoA desaturase 1 (SCD1) inhibitor, with the initiative focused on leveraging Barcode's specialized delivery platform to enhance Aramchol's therapeutic reach …
Virax Biolabs (NASDAQ: VRAX) issued a corporate update detailing a meaningfully strengthened financial position, commercial progress, and regulatory compliance restoration that collectively represent a significant improvement in the company's operational stability and near-term commercial trajectory.
Arbutus Biopharma (NASDAQ: ABUS) initiated fresh patent litigation in Canada and before the Unified Patent Court against Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), targeting the mRNA-LNP technologies used in their COVID-19 vaccines — continuing a pattern of IP enforcement that has already produced …
Two developments released in close proximity have transformed the investment and regulatory landscape for psychedelic medicine: the US Food and Drug Administration's publication of its final guidance on psychedelic drug clinical investigations, and Eli Lilly and Company's (NYSE: LLY) definitive agreement to acquire AtaiBeckley …
The presentation will specifically highlight baseline characteristics correlated with a confirmed loss of 15 letters in Best Corrected Visual Acuity (BCVA) among patients with geographic atrophy. BCVA is a standard clinical measure of vision quality used extensively in ophthalmology trials, and a 15-letter loss …
VDPHL01 is a specialized gel-matrix oral minoxidil engineered for extended release, designed to sustain therapeutic growth-promoting levels of the drug while mitigating cardiovascular risks that have historically been linked to traditional immediate-release oral minoxidil formulations. This extended-release engineering approach represents an important potential advancement, …
A 31% confirmed response rate is a clinically meaningful efficacy signal for an allogeneic, or 'off-the-shelf,' CAR-T cell therapy in a solid tumor indication like clear cell renal cell carcinoma. CAR-T therapies have historically achieved their most dramatic successes in blood cancers, and demonstrating …
Please wait processing your request...